Interleukin-22 promotes cancer stemness and chemotherapy resistance in colorectal cancer via epidermal growth factor receptor/extracellular signal-regulated kinase pathway

doi:10.4251/wjgo.v17.i8.108535

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 8

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (87)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-4) series.

Item

Count

PDF

HTML

Figures (1-4)

Sum=79

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=4

Aug 15, 2025 (publication date) through Aug 17, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

World J Gastrointest Oncol. Aug 15, 2025; 17(8): 108535
Published online Aug 15, 2025. doi: 10.4251/wjgo.v17.i8.108535

Interleukin-22 promotes cancer stemness and chemotherapy resistance in colorectal cancer via epidermal growth factor receptor/extracellular signal-regulated kinase pathway

Hong-Xun Ruan, Yan-Le Fang, Xiao-Ning Qin, Lin Lin

Hong-Xun Ruan, Yan-Le Fang, Xiao-Ning Qin, Lin Lin, The Third Department of General Surgery, The Second Hospital of Hebei Medical University, Shijiazhuang 050004, Hebei Province, China

Author contributions: Lin L designed and coordinated the study; Ruan HX acquired and analyzed data; Fang YL performed the experiments; Qin XN and Lin L wrote the manuscript; All authors read and approved the final version of the manuscript.

Institutional review board statement: The article does not involve humans or animals, so it does not require approval from an institutional review board.

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

Data sharing statement: The datasets generated and/or analyzed in the experiment are available from the corresponding author on reasonable request at linlin779242000@163.com.

Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Lin Lin, MD, The Third Department of General Surgery, The Second Hospital of Hebei Medical University, No. 215 Heping West Road, Shijiazhuang 050004, Hebei Province, China. linlin779242000@163.com

Received: April 17, 2025
Revised: May 26, 2025
Accepted: July 11, 2025
Published online: August 15, 2025
Processing time: 119 Days and 21.5 Hours

Core Tip

Core Tip: This study reveals that interleukin-22 (IL-22) enhances stem cell-like traits and promotes resistance to oxaliplatin in colorectal cancer (CRC) cells. Mechanistically, IL-22 activates the epidermal growth factor receptor (EGFR)/extracellular signal-regulated kinase signaling pathway. Inhibition of EGFR with osimertinib reverses IL-22-induced chemoresistance. These findings highlight IL-22 as a critical mediator of therapeutic resistance and a potential target for overcoming drug resistance in CRC treatment.